GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.…
Is GH Research (GHRS) Overvalued Even After Positive FDA Feedback?
GH Research (NASDAQ: GHRS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 73 employees.
The shares were at 17.53 USD on 20 November 2026, up 16.9% over 52 weeks. Its 52-week range is 12.04 USD to 31.44 USD: the price is 44.2% below the high and 45.6% above the low.
Its market capitalisation is 1.20B USD.
GH Research reports return on equity of -17.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 362.29M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 42.44 USD is 142.1% above the current price. The next earnings report is expected on 4 March 2027.